Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to NovationBio's first quarter 2026 financial results and corporate update call. Today's call is being recorded and a replay will be available on the company's website. All participants are currently in a listen only mode. A brief question and answer session will follow the prepared remarks. Now, I'd like to turn the call over to J.R. DeVita, Vice President of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead. Thank you, and good afternoon, everyone. Earlier today, we issued a press release summarizing our financial results for the quarter ending March 31st, 2026, and provided a business update. The press release is available on the investor section of our website at nuvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of Ibtrozi and Safucitinib, our plans for Safucitinib development and future data presentations, the components of our anticipated product revenue, expected milestone payments, and our cash runway. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10-Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our founder, president, and chief executive officer, Dr. David Hung, our chief commercial officer, Colleen Sjogren, and our chief financial officer, Philippe Sauvage. Now, I'll turn the call over to Dr. David Hung. David, please go ahead. Thanks, JR. Good afternoon, everyone, and thank you all for joining us. Today, I'm excited to discuss the progress w...